ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Shu‐Ling Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2895-225X; OpenAlex author ID A5043985731. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Design, synthesis, and evaluation of novel andrographolide derivatives as anti-pancreatic cancer therapeutics. Last author DOI 10.1016/j.bioorg.2026.109946 ↗
Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382. Last author DOI 10.1016/j.phymed.2024.155860 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yun-Ruei Li · 1 shared paper, 2026 · strength 0.36
- Paper Design, synthesis, and evaluation of novel andrographolide derivatives as anti-pancreatic cancer therapeutics. DOI 10.1016/j.bioorg.2026.109946 ↗
Kai-Ru Zhuang · 1 shared paper, 2024 · strength 0.19
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗
Shin‐E Wang · 1 shared paper, 2024 · strength 0.19
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗
Bor‐Uei Shyr · 1 shared paper, 2024 · strength 0.19
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.